Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

New lipid-lowering agents.

Anthony S Wierzbicki1

  • 1Department of Chemical Pathology, St. Thomas' Hospital Campus, Lambeth Palace Road, London, SE1 7EH, UK. Anthony.Wierzbicki@kcl.ac.uk

Expert Opinion on Emerging Drugs
|December 10, 2003
PubMed
Summary

New lipid-lowering therapies are emerging, including novel statins and cholesterol absorption inhibitors. Research also explores targets like squalene synthase and CETP for atherosclerosis treatment.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Diagnosis and Metabolic Management of Adult Refsum Disease: Guidance From the Medical and Scientific Committee of Global DARE (Defeat Adult Refsum Everywhere).

Journal of inherited metabolic disease·2026
Same author

Adult Refsum Disease: Case Series of Reducing Circulating Phytanic Acid Levels With Dietary Interventions.

JIMD reports·2026
Same author

Dopaminergic modulation of pancreatic beta-cell insulin secretion and implications for antipsychotic-induced glucose dysregulation: a systematic review and meta-analysis.

Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology·2026
Same author

Systematic identification of familial hypercholesterolaemia: An updated systematic review and meta-analysis.

Atherosclerosis·2026
Same author

<i>Ex vivo</i> expanded human regulatory T cells promote cholesterol efflux and PON1 expression in oxLDL-exposed macrophages via gap junction-mediated cAMP transfer.

Frontiers in immunology·2025
Same author

Rare variant genetic landscape of familial chylomicronemia syndrome (FCS) in the United Kingdom.

Genetics in medicine open·2025

Area of Science:

  • Cardiovascular Pharmacology
  • Atherosclerosis Therapeutics
  • Lipid Metabolism Research

Background:

  • Lipid-lowering interventions are proven to reduce atherosclerosis and its complications.
  • Existing therapies provide a foundation for developing novel treatments.

Purpose of the Study:

  • To summarize upcoming advancements in lipid-lowering therapy.
  • To highlight emerging drug targets and compounds in development for atherosclerosis.

Main Methods:

  • Review of ongoing clinical investigations for new statins and cholesterol absorption inhibitors.
  • Discussion of compounds targeting squalene synthase, MTP, ACAT, CETP, PPARs, and Lp(a) in preclinical and animal models.

Main Results:

  • Several novel lipid-lowering agents are nearing licensing.
  • Compounds targeting various pathways have shown promise in animal models.

Conclusions:

  • The field of lipid-lowering drugs is rapidly evolving with novel treatment options.
  • Potential synergies between new and existing compounds offer promising avenues for atherosclerosis management.

Related Experiment Videos